Eric Venker Biography and Net Worth

CEO of Immunovant

Eric Venker, MD, PharmD, is the Chief Executive Officer of Immunovant and has served on the Board of Directors since 2020. He brings more than two decades of clinical practice and operating experience to the company. Dr. Venker also serves as the President of Roivant Sciences, a position he has held since 2018. Dr. Venker first joined Roivant in 2014 and has held various roles of increasing responsibility, including Chief Medical Officer, Chief of Staff to the CEO, and most recently, Chief Operating Officer. Earlier in his career, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. Dr. Venker received his M.D. from the Yale School of Medicine and his Pharm.D. from the St. Louis College of Pharmacy.

What is Eric Venker's net worth?: The estimated net worth of Eric Venker is at least $9.82 million as of July 2nd, 2026. Venker owns 254,280 shares of Immunovant stock worth more than $9,815,208 as of July 6th. This net worth evaluation does not reflect any other investments that Venker may own. Learn More about Eric Venker's net worth.
How do I contact Eric Venker?: The corporate mailing address for Venker and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Eric Venker's contact information.
Has Eric Venker been buying or selling shares of Immunovant?: During the last quarter, Eric Venker has sold $118,980.16 in shares of Immunovant stock. Most recently, Eric Venker sold 3,092 shares of the business's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $38.48, for a transaction totalling $118,980.16. Following the completion of the sale, the chief executive officer now directly owns 254,280 shares of the company's stock, valued at $9,784,694.40. Learn More on Eric Venker's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Andrew Fromkin (Director), Michael Geffner (Chief Medical Officer), Tiago Girão (CFO), Melanie Gloria (COO), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), Frank Torti (Director), Christopher Van Tuyl (Chief Legal Officer and Corporate Secretary), and Eric Venker (CEO). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,666,666 shares worth more than $349,999,986.00. During the last twelve months, insiders at the sold shares 30 times. They sold a total of 469,931 shares worth more than $14,830,509.44. The most recent insider tranaction occured on July, 2nd when CEO Eric Venker sold 3,092 shares worth more than $118,980.16. Insiders at Immunovant own 1.8% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 7/2/2026.

Eric Venker Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/2/2026	Sell	3,092	$38.48	$118,980.16	254,280
4/2/2026	Sell	14,229	$24.10	$342,918.90	19,561

Eric Venker Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $38.60

$38.26

$39.23

50 Day Range

MA: $32.46

$26.29

$38.85

2 Week Range

Now: $38.60

$14.32

$39.28

Volume

1,066,390 shs

Average Volume

1,657,724 shs

Market Capitalization

$7.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76